Adverum Biotechnologies Inc. (ADVM), a clinical-stage company pioneering the use of gene therapy for ocular diseases, has an important catalyst to watch in the coming months.
The company is slated to present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of Ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com